[go: up one dir, main page]

ATE366117T1 - Membranvesikel (omv) mit verbesserten eigenschaften - Google Patents

Membranvesikel (omv) mit verbesserten eigenschaften

Info

Publication number
ATE366117T1
ATE366117T1 AT03791150T AT03791150T ATE366117T1 AT E366117 T1 ATE366117 T1 AT E366117T1 AT 03791150 T AT03791150 T AT 03791150T AT 03791150 T AT03791150 T AT 03791150T AT E366117 T1 ATE366117 T1 AT E366117T1
Authority
AT
Austria
Prior art keywords
pellet
membrane vesicles
collecting
detergent
outer membrane
Prior art date
Application number
AT03791150T
Other languages
English (en)
Inventor
Mariagrazia Pizza
Davide Serruto
Rini Rappuoli
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9943238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE366117(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE366117T1 publication Critical patent/ATE366117T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/06—Lysis of microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Materials For Medical Uses (AREA)
AT03791150T 2002-08-30 2003-09-01 Membranvesikel (omv) mit verbesserten eigenschaften ATE366117T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0220194.5A GB0220194D0 (en) 2002-08-30 2002-08-30 Improved vesicles

Publications (1)

Publication Number Publication Date
ATE366117T1 true ATE366117T1 (de) 2007-07-15

Family

ID=9943238

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03791150T ATE366117T1 (de) 2002-08-30 2003-09-01 Membranvesikel (omv) mit verbesserten eigenschaften

Country Status (21)

Country Link
US (2) US20060166344A1 (de)
EP (5) EP2258390A1 (de)
JP (3) JP2006503822A (de)
CN (2) CN102188700A (de)
AT (1) ATE366117T1 (de)
AU (1) AU2003263534B2 (de)
BR (1) BRPI0314094A8 (de)
CA (1) CA2497165C (de)
CY (3) CY1107737T1 (de)
DE (1) DE60314756T2 (de)
DK (3) DK1864679T3 (de)
ES (4) ES2520392T3 (de)
FR (1) FR13C0046I2 (de)
GB (1) GB0220194D0 (de)
LU (1) LU92239I2 (de)
MX (1) MXPA05002316A (de)
NZ (1) NZ538673A (de)
PT (3) PT1864679E (de)
RU (1) RU2325184C2 (de)
SI (2) SI2258389T1 (de)
WO (1) WO2004019977A2 (de)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG152917A1 (en) * 1998-01-14 2009-06-29 Chiron Srl Neisseria meningitidis antigens
ES2278446T3 (es) 1998-05-29 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Vacunas combinadas b/c contra la meningitis.
EP1860191A3 (de) 1999-05-19 2008-02-13 Novartis Vaccines and Diagnostics S.r.l. Neisseria Kombinationzusammensetzungen
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
EP2275129A3 (de) 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Ergänzter Außenmembranvesikel-Impfstoff gegen Meningokokken
ES2519440T3 (es) 2000-07-27 2014-11-07 Children's Hospital & Research Center At Oakland Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CU23377A1 (es) * 2003-11-04 2009-05-28 Ct De Ingenieria Genetica Y Biotecnologia Metodo para la incorporacion de antigenos en vesiculas de membrana externa de bacterias y formulaciones resultantes
GB0416120D0 (en) 2004-07-19 2004-08-18 Health Prot Agency Stable compositions containing OMV's
EP1789094B1 (de) 2004-08-13 2014-12-10 MARSHALL, Barry J. Bakterielles abgabesystem
US8029777B2 (en) * 2004-08-13 2011-10-04 Marshall Barry J Helicobacter system and uses thereof
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
DK2682126T3 (en) 2005-01-27 2017-02-27 Children's Hospital & Res Center At Oakland GNA1870-based vesicle vaccines for broad-spectrum protection against diseases caused by Neisseria meningitidis
US8062644B2 (en) * 2005-02-18 2011-11-22 Novartis Vaccines & Diagnostics Srl. Immunogens from uropathogenic Escherichia coli
GB2441094B (en) * 2005-05-19 2010-11-03 Edward Jenner Inst For Vaccine Methods for treatment and prevention of infection
PL2878307T3 (pl) 2005-06-27 2020-01-31 Glaxosmithkline Biologicals S.A. Kompozycja immunogenna
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
AU2016204760A1 (en) * 2006-04-26 2016-07-28 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2014268186C1 (en) * 2006-04-26 2017-12-07 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
NZ584683A (en) 2007-10-19 2012-05-25 Novartis Ag Neisseria meningitidis serogroup B vaccine formulations
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
BRPI0923006A2 (pt) 2008-12-17 2016-03-08 Novartis Ag vacinas meningococicas incluindo receptor de hemoglobina
ES2797504T3 (es) 2009-03-24 2020-12-02 Glaxosmithkline Biologicals Sa Proteína de enlace del factor H meningocócico utilizada como adyuvante
NZ595361A (en) * 2009-04-30 2013-09-27 Childrens Hosp & Res Ct Oak Chimeric factor h binding proteins (fhbp) and methods of use
CN102762226A (zh) 2009-06-10 2012-10-31 诺华有限公司 含苯并萘啶的疫苗
WO2011022229A2 (en) * 2009-08-20 2011-02-24 Srisuda Dhamwichukorn Method for enhanced sustainable production of algal bio-products, comprising use of symbiotic diazotroph-attenuated stress co-cultivation
CN102740882A (zh) 2009-08-27 2012-10-17 诺华有限公司 含有铝、寡核苷酸和聚阳离子的佐剂
BR112012004275A2 (pt) 2009-08-27 2016-11-16 Novartis Ag polipeptídios híbridos incluindo sequências meningocócicas de fhbp
WO2011027956A2 (ko) 2009-09-04 2011-03-10 주식회사이언메딕스 그람 양성 박테리아에서 유래한 세포밖 소포체 및 이를 이용한 질병 모델
WO2011027971A2 (ko) * 2009-09-01 2011-03-10 주식회사이언메딕스 장내 공생 세균유래 세포밖 소포체, 및 이를 이용한 질병모델, 백신, 후보 약물 탐색 방법, 및 진단 방법
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
WO2011039631A2 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
EP2493499A1 (de) 2009-10-27 2012-09-05 Novartis AG Modifizierte meningokokken-fhbp-polypeptide
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
US9408907B2 (en) 2009-12-15 2016-08-09 Glaxosmithkline Biologicals Sa Homogenous suspension of immunopotentiating compounds and uses thereof
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
JP5848748B2 (ja) 2010-03-23 2016-01-27 アイアールエム・リミテッド・ライアビリティ・カンパニーＩｒｍ，Ｌｌｃ 感染症、炎症、呼吸器疾患などの処置に使用するｔｌｒ２アゴニストとしての化合物（システインベースのリポペプチド）および組成物
CN103079592B (zh) 2010-07-01 2015-10-21 浦项工科大学校产学协力团 使用来自细胞的微泡治疗和诊断癌症的方法
PT3246044T (pt) 2010-08-23 2021-02-15 Wyeth Llc Formulações estáveis de antigénios de rlp2086 de neisseria meningitidis
AU2011300418B2 (en) 2010-09-10 2016-05-12 Glaxosmithkline Biologicals Sa Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
WO2012153302A1 (en) 2011-05-12 2012-11-15 Novartis Ag Antipyretics to enhance tolerability of vesicle-based vaccines
CA2840096C (en) * 2011-07-07 2021-07-06 Bas VAN DE WATERBEEMD A process for detergent-free production of outer membrane vesicles of a gram-negative bacterium
MX2014008988A (es) 2012-02-02 2014-08-27 Novartis Ag Promotores para aumento de expresion de proteinas en meningococo.
US10598666B2 (en) 2012-03-08 2020-03-24 Glaxosmithkline Biologicals Sa In vitro potency assay for protein-based meningococcal vaccines
US8986710B2 (en) 2012-03-09 2015-03-24 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP2833911A4 (de) 2012-04-06 2016-07-13 Univ Cornell Untereinheiten-impfstoffabgabeplattform für robuste humorale und zelluläre immunantworten
US10376573B2 (en) 2012-06-14 2019-08-13 Glaxosmithkline Biologicals Sa Vaccines for serogroup X meningococcus
AU2013295242C1 (en) 2012-07-27 2018-08-09 Institut National De La Sante Et De La Recherche Medicale CD147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
RU2015106930A (ru) 2012-09-06 2016-10-20 Новартис Аг Комбинированные вакцины с менингококком серогруппы в и к/д/с
RU2662970C2 (ru) 2012-09-18 2018-07-31 Новартис Аг Везикулы наружной мембраны
US20160120818A1 (en) 2013-02-07 2016-05-05 Glaxosmithline Biological Sa Pharmaceutical compositions comprising vesicles
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
CA2940447C (en) 2014-02-28 2023-07-11 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
US11066453B2 (en) 2015-05-18 2021-07-20 Biomvis Srl Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
US10835601B2 (en) * 2015-11-10 2020-11-17 Ohio State Innovation Foundation Methods and compositions related to accelerated humoral affinity
JP7104027B2 (ja) 2016-09-02 2022-07-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 淋菌に対するワクチン
AU2017347870B2 (en) * 2016-10-28 2024-05-23 Vedanta Biosciences, Inc. Methods and compositions for preserving bacteria
SG10202111092UA (en) 2017-01-31 2021-11-29 Pfizer Neisseria meningitidis compositions and methods thereof
CN110891599A (zh) * 2017-03-31 2020-03-17 印度医学研究理事会 基于来自伤寒样沙门菌物种的两种不同菌株的外膜囊泡的肠热疫苗
AR113011A1 (es) 2017-09-08 2020-01-15 Evelo Biosciences Inc Vesículas extracelulares bacterianas
US10793865B2 (en) 2018-06-05 2020-10-06 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Transferrable mechanism of generating inducible, BAR domain protein-mediated bacterial outer membrane extensions
EP3607967A1 (de) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modifizierte meningokokken fhbp polypeptide
AU2019376832B2 (en) 2018-11-06 2024-01-25 Glaxosmithkline Biologicals Sa Immunogenic compositions
WO2020172492A2 (en) * 2019-02-22 2020-08-27 Evelo Biosciences, Inc. Bacterial membrane preparations
US20220378902A1 (en) * 2019-08-22 2022-12-01 Sichuan University Bacterial membrane vesicles, and separation and preparation system and method therefor
CN110563829B (zh) * 2019-09-17 2021-03-26 中国人民解放军国防科技大学 用于调控脂质体囊泡行为、功能的反光蛋白体系及其应用
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3799884A1 (de) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogene zusammensetzungen
US20230321213A1 (en) 2020-09-11 2023-10-12 Glaxosmithkline Biologicals Sa Outer membrane vesicles
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
WO2023097652A1 (en) * 2021-12-03 2023-06-08 National Center For Nanoscience And Technology An engineered cell and application thereof
GB202211033D0 (en) 2022-07-28 2022-09-14 Glaxosmithkline Biologicals Sa Purification process

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
RU2023448C1 (ru) 1987-07-30 1994-11-30 Сентро Насьональ Де Биопрепарадос Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
WO1990006696A2 (en) 1988-12-19 1990-06-28 Praxis Biologics, Inc. Meningococcal class 1 outer-membrane protein vaccine
EP0378881B1 (de) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
EP0482068A1 (de) 1989-07-14 1992-04-29 American Cyanamid Company Cytokin- und hormonträger zur verwendung bei konjugatimpfstoffen
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
EP0471177B1 (de) 1990-08-13 1995-10-04 American Cyanamid Company Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff
US5993826A (en) 1993-03-02 1999-11-30 Board Of Regents, The University Of Texas Methods and compositions relating to useful antigens of moraxella catarrhalis
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
WO1993018150A1 (en) 1992-03-02 1993-09-16 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
FR2692592B1 (fr) * 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
EP0761231B1 (de) 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Adjuvantien enthaltende Impfstoffzusammensetzung
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
NL9201716A (nl) 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
ES2145072T3 (es) 1993-05-13 2000-07-01 American Cyanamid Co Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ES2128055T3 (es) * 1994-04-20 1999-05-01 Us Army Vacuna contra infecciones de bacterias gram-negativas.
JPH10502365A (ja) 1994-07-01 1998-03-03 リカン・リミテッド ヘリコバクタータンパク質およびワクチン
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0772619B2 (de) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatorische oligonukleotide
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
AU707131B2 (en) 1995-08-04 1999-07-01 University Of Guelph Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
GB2324093A (en) 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
DE19630390A1 (de) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
ES2195317T3 (es) 1997-01-30 2003-12-01 Chiron Corp Uso de microparticulas con antigeno adsorbido para estimular respuestas inmunitarias.
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
EP1005368B1 (de) 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien
DE69838294T2 (de) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
ATE432348T1 (de) 1997-06-06 2009-06-15 Univ California Inhibitoren von immunstimulatorischen dna sequenz aktivität
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
AU748973B2 (en) * 1997-07-17 2002-06-13 Baxter Healthcare Sa Immunogenic conjugates comprising a group B meningococcal porin and an H. influenzae polysaccharide
CA2300854C (en) 1997-08-21 2011-04-05 Peter Andre Van Der Ley Novel mutants of gram negative mucosal bacteria and application thereof in vaccines
DE69838992T2 (de) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
ATE476508T1 (de) 1997-11-06 2010-08-15 Novartis Vaccines & Diagnostic Neisseriale antigene
BR9814878A (pt) 1997-11-21 2000-10-03 Genset Sa Sequência genÈmica e polipeptìdeos de chlamydia pneumoniae, fragmentos dos mesmos e usos dos mesmos, em particular para o diagnóstico, a prevenção e o tratamento de infecção
BR9814912A (pt) 1997-11-28 2000-10-03 Genset Sa Sequência genÈmica e polipeptìdeos de chlamydia trachomatis, fragmentos dos mesmos e usos dos mesmos, em particular para o diagnóstico, a prevenção e o tratamento de infecção
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
SG152917A1 (en) 1998-01-14 2009-06-29 Chiron Srl Neisseria meningitidis antigens
GB9806456D0 (en) * 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
EP2261341A3 (de) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Antigene und Zusammensetzungen gegen Neisseria meningitidis
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
CN1338005A (zh) 1998-10-09 2002-02-27 希龙公司 奈瑟球菌基因组序列及其用途
CZ301212B6 (cs) 1998-10-16 2009-12-09 Smithkline Beecham Biologicals S. A. Vakcinacní prostredek
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
EP1133572A4 (de) 1998-11-12 2005-06-15 Univ California Genomsequenz von chlamydia pneumoniae
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
PT1150712E (pt) * 1999-02-05 2008-12-22 Merck & Co Inc Formulações para a vacina do vírus do papiloma humano
US7081244B2 (en) * 1999-02-22 2006-07-25 Health Protection Agency Neisserial vaccine compositions and methods
DK1154791T3 (da) 1999-02-22 2008-06-16 Health Prot Agency Neisseria-vaccinesammensætninger og fremgangsmåder
DE69942774D1 (de) 1999-02-26 2010-10-28 Novartis Vaccines & Diagnostic Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen
EP1162999B1 (de) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Impstoff gegen Streptococcus pneumoniae
US6245568B1 (en) * 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
JP2002541808A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
TR200103018T2 (tr) 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
EP1228217B1 (de) 1999-04-30 2012-11-21 Novartis Vaccines and Diagnostics S.r.l. Konservierte antigene aus neisseria
AUPQ005499A0 (en) * 1999-04-30 1999-05-27 Townsend, Roy Leslie Printing process
EP1860191A3 (de) 1999-05-19 2008-02-13 Novartis Vaccines and Diagnostics S.r.l. Neisseria Kombinationzusammensetzungen
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
JP2003509473A (ja) 1999-09-24 2003-03-11 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
KR20020048942A (ko) 1999-09-24 2002-06-24 장 스테판느 폴리옥시에틸렌 알킬 에테르 또는 에스테르 및 하나이상의 비이온성 계면활성제를 포함하는 애쥬번트
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
EP2275129A3 (de) 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Ergänzter Außenmembranvesikel-Impfstoff gegen Meningokokken
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
GB0007433D0 (en) * 2000-03-27 2000-05-17 Microbiological Res Authority Recombinant transferrin binding proteins
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
ATE440861T1 (de) 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae
GB0017149D0 (en) 2000-07-12 2000-08-30 Chiron Spa Helicobacter pylori mutants
ES2519440T3 (es) * 2000-07-27 2014-11-07 Children's Hospital & Research Center At Oakland Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
CN101428006A (zh) 2000-09-28 2009-05-13 诺华疫苗和诊断公司 微粒体组合物及其生产方法
WO2002034771A2 (en) 2000-10-27 2002-05-02 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
GB0103171D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
WO2003009869A1 (en) 2001-07-26 2003-02-06 Chiron Srl. Vaccines comprising aluminium adjuvants and histidine
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
GB0130123D0 (en) * 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
DK2255826T3 (en) * 2002-08-02 2016-06-20 Glaxosmithkline Biologicals Sa Neisserial vaccine compositions comprising a combination of antigens.

Also Published As

Publication number Publication date
ES2289351T3 (es) 2008-02-01
AU2003263534B2 (en) 2010-08-05
RU2325184C2 (ru) 2008-05-27
EP2258388A1 (de) 2010-12-08
ES2423019T3 (es) 2013-09-17
BR0314094A (pt) 2005-11-16
EP1864679A3 (de) 2008-04-02
EP1864679A2 (de) 2007-12-12
EP1534326B1 (de) 2007-07-04
DK2258389T3 (da) 2013-08-26
SI2258389T1 (sl) 2013-07-31
FR13C0046I2 (fr) 2014-05-16
EP2258389A1 (de) 2010-12-08
EP1864679B1 (de) 2014-06-18
EP2258389B1 (de) 2013-06-05
DE60314756D1 (de) 2007-08-16
JP2010150287A (ja) 2010-07-08
CN1688334A (zh) 2005-10-26
CN102188700A (zh) 2011-09-21
DE60314756T2 (de) 2008-03-06
DK1534326T3 (da) 2007-10-22
JP2013139471A (ja) 2013-07-18
SI1864679T1 (sl) 2014-10-30
FR13C0046I1 (de) 2013-09-06
AU2003263534A1 (en) 2004-03-19
CA2497165C (en) 2015-10-20
JP2006503822A (ja) 2006-02-02
ES2520392T3 (es) 2014-11-11
GB0220194D0 (en) 2002-10-09
CY1107737T1 (el) 2013-04-18
WO2004019977A2 (en) 2004-03-11
EP1534326A2 (de) 2005-06-01
US20060166344A1 (en) 2006-07-27
CY1114570T1 (el) 2017-01-25
EP2258390A1 (de) 2010-12-08
NZ538673A (en) 2008-04-30
CY1115777T1 (el) 2017-01-25
US20150258188A1 (en) 2015-09-17
DK1864679T3 (da) 2014-08-25
PT2258389E (pt) 2013-08-22
PT1534326E (pt) 2007-10-17
BRPI0314094A8 (pt) 2018-04-03
RU2005108994A (ru) 2006-02-10
LU92239I2 (fr) 2013-09-04
PT1864679E (pt) 2014-09-25
ES2483592T3 (es) 2014-08-06
JP5808358B2 (ja) 2015-11-10
MXPA05002316A (es) 2005-06-08
WO2004019977A3 (en) 2004-07-15
EP2258388B1 (de) 2014-08-13
CA2497165A1 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
ATE366117T1 (de) Membranvesikel (omv) mit verbesserten eigenschaften
JP2006503822A5 (de)
DE60045034D1 (de) Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen
WO2007076520A3 (en) Multivalent pcv2 immunogenic compositions and methods of producing such compositions
CN103820412B (zh) 用于临床手术创伤的快速止血产品及其制备方法和应用
BR0108711A (pt) Expressão heteróloga de proteìnas de neisseria
DK1296711T3 (da) HPV-E7 til behandling af humant papillomavirus
ATE469915T1 (de) Antikörper gegen das meningokokken adhäsin app
WO2000067774A3 (en) Materials for soft tissue augmentation and methods of making and using same
DK0909323T3 (da) Helicobacter pylori-bakterioferritin
WO2004060303A3 (en) Methods and reagents for the enhancement of virus transduction in the bladder epithelium
CA2386126A1 (en) Method of improving gene transfer efficiency into plant cells
WO2003060520A3 (en) Sample preparation for the detection of infectious agents
DE60330004D1 (de) Impfung mit immunisolierten und einen immunomodulator produzierenden zellen
SI1127943T1 (sl) Sredstva in postopki za ekspresijo homolognih in heterolognih proteinov v sevih Rhodococcus
ATE496745T1 (de) Holzbehandlungsmethode
WO2009120302A3 (en) Chemical treatments to enhance photovoltaic performance of cigs
CN102041253A (zh) 一种蛇毒蛋白的提取工艺
WO2002066053A3 (en) Method of treating or preventing disease characterized by cryptococcus neoformans infection
CN101412988A (zh) 孔雀石绿等三苯基甲烷类染料降解酶TpmD的制备方法
Nagel Extraction and Fractionation of B. pertussis Antigens In Order To Reduce The Reactogenic Properties of Pertussis Vaccines J. Nagel and S. de Graaf
ES8605576A1 (es) Un procedimiento para preparar una composicion contra infecciones virales de hepatitis b
RU99102863A (ru) Способ повышения эксплуатационных свойств абразивного инструмента
CN1710072A (zh) 分泌人白介素－2的重组卡介苗及其构建方法
CN1710073A (zh) 分泌肿瘤坏死因子－α的重组卡介苗及其构建方法